Display options
Cite
Hong KP, Byun YJ, Yoon H, et al. Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia. Korean J Urol. 2010;51(7):488-91doi: 10.4111/kju.2010.51.7.488.
Hong, K. P., Byun, Y. J., Yoon, H., Park, Y. Y., & Chung, W. S. (2010). Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia. Korean journal of urology, 51(7), 488-91. https://doi.org/10.4111/kju.2010.51.7.488
Hong, Kyoung Pyo, et al. "Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia." Korean journal of urology vol. 51,7 (2010): 488-91. doi: https://doi.org/10.4111/kju.2010.51.7.488
Hong KP, Byun YJ, Yoon H, Park YY, Chung WS. Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia. Korean J Urol. 2010 Jul;51(7):488-91. doi: 10.4111/kju.2010.51.7.488. Epub 2010 Jul 20. PMID: 20664783; PMCID: PMC2907499.
Copy Download .nbib Format: NLM
Share it on

Korean J Urol. 2010 Jul;51(7):488-91. doi: 10.4111/kju.2010.51.7.488. Epub 2010 Jul 20.

Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia.

Korean journal of urology

Kyoung Pyo Hong, Young Joon Byun, Hana Yoon, Young Yo Park, Woo Sik Chung

Affiliations

  1. Department of Urology, Ewha Womans University School of Medicine, Seoul, Korea.

PMID: 20664783 PMCID: PMC2907499 DOI: 10.4111/kju.2010.51.7.488

Abstract

PURPOSE: We aimed to determine the treatment of choice criteria for benign prostatic hyperplasia (BPH) by analyzing the factors causing alpha-adrenergic receptor blocker (alpha-blocker) monotherapy failure.

MATERIALS AND METHODS: This retrospective study enrolled 129 patients with BPH who were prescribed an alpha-blocker. Patients were allocated to a transurethral resection of prostate (TURP) group (after having at least a 6-month duration of medication) and an alpha-blocker group. We compared the differences between the two groups for their initial prostate volume, serum prostate-specific antigen (PSA), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), and postvoid residual urine volume (PVR).

RESULTS: Of the 129 patients, 54 were in the TURP group and 75 were in the alpha-blocker group. Statistically significant differences (p<0.05) between the two groups were found in the prostate volume (50.8 ml vs. 34.4 ml), PSA (6.8 ng/ml vs. 3.6 ng/ml), Qmax (6.84 ml/sec vs. 9.99 ml/sec), and IPSS (27.3 vs. 16.8). According to the multiple regression analysis, the significant factors in alpha-blocker monotherapy failure were the IPSS (p<0.001) and prostate volume (p=0.015). According to the receiver operating characteristic (ROC) curve-based prediction regarding surgical treatment, the best cutoff value for the prostate volume and IPSS were 35.65 ml (sensitivity 0.722, specificity 0.667) and 23.5 (sensitivity 0.852, specificity 0.840), respectively.

CONCLUSIONS: At the initial diagnosis of BPH, patients with a larger prostate volume and severe IPSS have a higher risk of alpha-blocker monotherapy failure. In this case, combined therapy with 5-alpha-reductase inhibitor (5-ARI) or surgical treatment may be useful.

Keywords: Adrenergic alpha-antagonists; Prostatic hyperplasia; Transurethral resection of prostate

References

  1. BJU Int. 2006 Apr;97(4):734-41 - PubMed
  2. Urology. 2006 Nov;68(5):1015-9 - PubMed
  3. Eur Urol. 2003 Jul;44(1):94-9; discussion 99-100 - PubMed
  4. BJU Int. 2004 Mar;93 Suppl 1:27-9 - PubMed
  5. Eur Urol. 2000 Nov;38(5):563-8 - PubMed
  6. J Urol. 1997 Aug;158(2):481-7 - PubMed
  7. J Urol. 2006 Apr;175(4):1422-6; discussion 1426-7 - PubMed
  8. Urology. 2004 Dec;64(6):1144-8 - PubMed
  9. N Engl J Med. 2003 Dec 18;349(25):2387-98 - PubMed
  10. Urology. 1999 Mar;53(3):473-80 - PubMed
  11. Eur Urol. 2004 Nov;46(5):547-54 - PubMed
  12. Urology. 1996 Sep;48(3):398-405 - PubMed
  13. J Urol. 2000 Jan;163(1):107-13 - PubMed
  14. Urology. 2004 Dec;64(6):1081-8 - PubMed

Publication Types